1. Calabresi P Radue EW Goodin D Jeffery D Kottil R Reder A Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS): results from an additional 24-month double-blind, placebo-controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States Neurology 2012
2. Calabresi PA Goodin D Jeffery D Kappos L Lublin FD Rammohan K Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing-remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France Multiple Sclerosis 2012
3. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;The Lancet Neurology,2014
4. Coyle P Cree B Cabre P Inglese M Perumal J Meng X Fingolimod efficacy and safety in an African-American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States Neurology 2014
5. Goodin D Jeffery D Kappos L Lublin F Radue EW Rammohan K Fingolimod reduces annualized relapse rate in patients with relapsing-remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States Neurology 2013